Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics Inc., a biotechnology company focused on developing next generation therapies for rare diseases, and brings over 15 years of experience in the orphan drug industry. He is a member of the BioNJ Board of Directors and is Amicus’ representative on the Health Care Initiative of New Jersey Board of Trustees. Prior to Amicus, Mr. Campbell held positions of increasing responsibility at Genzyme and Bristol-Myers Squibb and as strategy consultant for Marakon Associates. He is also past President of the National Tay-Sach and Allied Diseases Association Board of Directors and currently services on their Corporate Advisory Council. Mr. Campbell received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School. Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics Inc., a biotechnology company focused on developing next generation therapies for rare diseases, and brings over 15 years of experience in the orphan drug industry. He is a member of the BioNJ Board of Directors and is Amicus’ representative on the Health Care Initiative of New Jersey Board of Trustees. Prior to Amicus, Mr. Campbell held positions of increasing responsibility at Genzyme and Bristol-Myers Squibb and as strategy consultant for Marakon Associates. He is also past President of the National Tay-Sach and Allied Diseases Association Board of Directors and currently services on their Corporate Advisory Council. Mr. Campbell received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

Business Development